Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI

Magnetic Resonance in Medicine

Volumn 36, Issue 6, 1996, Pages 868-877

  Su, Min Ying ^a   Wang, Zhiheng ^a   Roth, Gerald M ^a   Lao, Xiaoyan ^a   Samoszuk, Michael K ^a   Nalcioglu, Orhan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer therapy; dynamic Gd DTPA enhanced MRI; pharmacokinetics; vasomodulators

Indexed keywords

HEMODYNAMICS; HISTOLOGY; MUSCLE; PHARMACOKINETICS; RATS; TISSUE ENGINEERING; TUMORS;

ABNORMAL TISSUES; ANGIOTENSIN II; CANCER THERAPY; GD-DTPA; RENAL BLOOD FLOW; SIGNAL INTENSITIES; SMALL MOLECULES; VASOMODULATORS;

BLOOD;

ANGIOTENSIN; CONTRAST MEDIUM; GADOLINIUM PENTETATE; HISTAMINE; HYDRALAZINE; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CANCER CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; MUSCLE BLOOD FLOW; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR BLOOD FLOW;

EID: 0029857166     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.1910360609     Document Type: Article

References (29)

1. D. J. Chaplin, The effect of therapy on tumour vascular function. Int. J. Radiat. Biol. 60, 311-325 (1991).
2. M. R. Horsman, D. J. Chaplin, J. Overgaard, The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother. Oncol. (Suppl.) 20, 47-52 (1991).
3. M. A. Burton, B. N. Gray, G. W. Self, J. C. Heggie, P. S. Townsend, Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. Cancer Res. 45, 5390-5393 (1985).
4. J. H. Anderson, N. Willmott, R. Bessent, W. J. Angerson, D. J. Kerr, C. S. McArdle, Regional chemotherapy for inoperable renal carcinoma: a method of targeting therapeutic microspheres to tumour. Br. J. Cancer 64, 365-368 (1991).
5. D. M. Hemingway, W. J. Angerson, J. H. Anderson, J. A. Goldberg, C. S. McArdle, T. G. Cooke, Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br. J. Cancer 66, 958-960 (1992).
6. S. V. Kozin, T. Hasegawa, S. K. Ha-Kawa, K. Akagi, Y. Tanaka, Hydralazine at thermoradiotherapy: tumor size and blood flow effects. Int. J. Radiat. Oncol. Biol. Phys. 29, 579-585 (1987).
7. D. J. Chaplin, B. Acker, The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int. J. Radiat. Oncol. Biol. Phys. 13, 505-510 (1994).
8. I. J. Stratford, G. E. Adams, J. Godden, J. Nolan, N. Howells, N. Timpson, Potentiation of anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br. J. Cancer 58, 122-127 (1988).
9. D. J. Chaplin, B. Acker, P. L. Olive, Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int. J. Radiat. Oncol. Biol. Phys. 16, 1131-1135 (1989).
10. D. J. Chaplin, Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy. J. Natl. Cancer Inst. 81, 618-622 (1989).
11. D. W. Siemann, Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br. J. Cancer 62, 348-353 (1990).
12. P. K. M. Quinn, M. C. Bibby, J. A. Cox, S. M. Crawford, The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MCA tumours. Br. J. Cancer 66, 323-330 (1992).
13. L. A. Khawli, G. K. Miller, A. L. Epstein, Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (Suppl. 3) 73, 824-831 (1994).
14. G. Majno, G. E. Palade, G. I. Schoefl, Studies on inflammation II. The site of action of histamine and serotonin along the vascular tree: a topological study. J. Biophys. Biochem. Cytol. 11, 607-626 (1961).
15. R. Jirtle, K. H. Clifton, J. H. G. Rankin, Effects of several vasoactive drugs on the vascular resistance of MT-W9B tumors in W/Fu rats. Cancer Res. 38, 2385-2390 (1978).
16. T. Hasegawa, C. W. Song, Effects of hydralazine on the blood flow in tumors and normal tissues in rats. Int. J. Radiat. Oncol. Biol. Phys. 20, 1001-1007 (1991).
17. T. Nomura, K. Ikezaki, Y. Natori, M. Fukui, Altered response to histamine in brain tumor vessels: the selective increase of regional cerebral blood flow in transplanted rat brain tumor. J. Neurosurg. 79, 722-728 (1993).
18. M.-Y. Su, J.-C. Jao, O. Nalcioglu, Measurements of vascular volume fraction and blood-tissue permeability constants with pharmacokinetic model: Studies in rat muscle tumor. Magn. Reson. Med. 32, 714-724 (1994).
19. M.-Y. Su, A. A. Najafi, O. Nalcioglu, Regional comparison of tumor vascularity and permeability parameters measured by albumin-Gd-DTPA and Gd-DTPA. Magn. Reson. Med. 34, 402-411 (1995).
20. C. A. Mistretta, Relative characteristics of MR angiography and competing vascular imaging modalities. J. Mag. Reson. Imaging 3, 685-698 (1993).
21. D. Shames, R. Kuwatsuru, V. Vexler, A. Muhler, and R. Brasch, Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn. Reson. Med. 29, 616-622 (1993).
22. R. Kuwatsuru, D. Shames, A. Muhler, J. Mintorovitch, V. Vexler, J. Mann, F. Cohn, D. Price, J. Huberty, and R. Brasch, Quantification of tissue plasma volume in the rat by contrast-enhanced magnetic resonance imaging. Magn. Reson. Med. 30, 76-81 (1993).
23. K. Hori, Q.-H. Zhang, S. Saito, S. Tanda, H.-C. Li, M. Suzuki, Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res. 53, 5528-5534 (1893).
24. L. Ekelund, A. Lunderquist, Pharmacoangiography with angiotensin. Radiology 110, 533-540 (1874).
25. K. Hori, M. Suzuki, S. Tanda, S. Saito, M. Shinozaki, Q.-H. Zhang, Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn. J. Cancer Res. 82, 1309-1316 (1991).
26. D. J. Honess, N. M. Bleehen, Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice. Int. J. Radiat. Oncol. Biol. Phys. 20, 953-961 (1992).
27. C. A. Belfi, L.-L. Ting, S. J. Hassenbusch, M. Tefft, F. Q. H. Ngo, Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 22, 477-482 (1992).
28. C. A. Belfi, C. R. Paul, S. Shan, F. Q. H. Ngo, Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI. Int. J. Radiat. Oncol. Biol. Phys. 29, 473-479 (1994).
29. G. Majno, V. Gilmore, M. Leventhal, On the mechanism of vascular leakage caused by histamine-type mediators. Circ. Res. 21, 833-847 (1967).